Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Efficacy and Safety of Bisphosphonates for Low Bone Mineral Density After Kidney Transplantation: A Meta-Analysis.

Kan SL, Ning GZ, Chen LX, Zhou Y, Sun JC, Feng SQ.

Medicine (Baltimore). 2016 Feb;95(5):e2679. doi: 10.1097/MD.0000000000002679. Review.

2.

Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.

Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE.

J Bone Miner Res. 2016 Jan;31(1):16-35. doi: 10.1002/jbmr.2708. Review.

3.

Alendronate as an effective treatment for bone loss and vascular calcification in kidney transplant recipients.

Okamoto M, Yamanaka S, Yoshimoto W, Shigematsu T.

J Transplant. 2014;2014:269613. doi: 10.1155/2014/269613. Epub 2014 Feb 19.

4.

Bisphosphonates for the prevention and treatment of osteoporosis in patients with rheumatic diseases: a systematic review and meta-analysis.

Feng Z, Zeng S, Wang Y, Zheng Z, Chen Z.

PLoS One. 2013 Dec 6;8(12):e80890. doi: 10.1371/journal.pone.0080890. eCollection 2013. Review.

5.

Evaluation and management of the premenopausal woman with low BMD.

Cohen A, Shane E.

Curr Osteoporos Rep. 2013 Dec;11(4):276-85. doi: 10.1007/s11914-013-0161-4.

6.

Premenopausal bone health: osteoporosis in premenopausal women.

Abraham A, Cohen A, Shane E.

Clin Obstet Gynecol. 2013 Dec;56(4):722-9. doi: 10.1097/GRF.0b013e3182a8ae55. Review.

7.

A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy.

Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, Brown JP, Cohen A, Kim H.

Allergy Asthma Clin Immunol. 2013 Aug 15;9(1):30. doi: 10.1186/1710-1492-9-30.

8.

Glucocorticoids and osteocyte autophagy.

Yao W, Dai W, Jiang JX, Lane NE.

Bone. 2013 Jun;54(2):279-84. doi: 10.1016/j.bone.2013.01.034. Epub 2013 Jan 26. Review.

9.

Glucocorticoid-induced osteoporosis: how best to avoid fractures.

Cooper MS.

Ther Adv Chronic Dis. 2010 Jan;1(1):17-23. doi: 10.1177/2040622310368737.

10.

Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation.

Shane E, Cohen A, Stein EM, McMahon DJ, Zhang C, Young P, Pandit K, Staron RB, Verna EC, Brown R, Restaino S, Mancini D.

J Clin Endocrinol Metab. 2012 Dec;97(12):4481-90. doi: 10.1210/jc.2012-2804. Epub 2012 Sep 28.

11.

Glucocorticoid-induced osteoporosis: treatment update and review.

Fraser LA, Adachi JD.

Ther Adv Musculoskelet Dis. 2009 Apr;1(2):71-85. doi: 10.1177/1759720X09343729.

12.

Glucocorticoid-induced osteoporosis - a disorder of mesenchymal stromal cells?

Hardy R, Cooper MS.

Front Endocrinol (Lausanne). 2011 Aug 27;2:24. doi: 10.3389/fendo.2011.00024. eCollection 2011.

13.

Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D.

Klaus J, Reinshagen M, Herdt K, Schröter C, Adler G, von Boyen GB, von Tirpitz C.

World J Gastroenterol. 2011 Jan 21;17(3):334-42. doi: 10.3748/wjg.v17.i3.334.

14.

Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid.

Li EK, Zhu TY, Hung VY, Kwok AW, Lee VW, Lee KK, Griffith JF, Li M, Wong KC, Leung PC, Qin L, Tam LS.

Arthritis Res Ther. 2010;12(5):R198. doi: 10.1186/ar3170. Epub 2010 Oct 22.

15.

Asthma and therapeutics: inhaled corticosteroids, corticosteroid osteoporosis, and the risk of fracture in chronic asthma.

Toogood JH.

Allergy Asthma Clin Immunol. 2005 Mar 15;1(1):28-33. doi: 10.1186/1710-1492-1-1-28. Epub 2005 Mar 15.

16.

Long-term anti-arthritic and anti-osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis.

Jochems C, Lagerquist M, HÃ¥kansson C, Ohlsson C, Carlsten H.

Clin Exp Immunol. 2008 Jun;152(3):593-7. doi: 10.1111/j.1365-2249.2008.03660.x. Epub 2008 Apr 24.

17.

Management of osteoporosis in men: an update and case example.

Khan AA, Hodsman AB, Papaioannou A, Kendler D, Brown JP, Olszynski WP.

CMAJ. 2007 Jan 30;176(3):345-8. Review.

18.

Glucocorticosteroid-induced spinal osteoporosis: scientific update on pathophysiology and treatment.

Popp AW, Isenegger J, Buergi EM, Buergi U, Lippuner K.

Eur Spine J. 2006 Jul;15(7):1035-49. Review.

19.

Influence of IL-6, COL1A1, and VDR gene polymorphisms on bone mineral density in Crohn's disease.

Todhunter CE, Sutherland-Craggs A, Bartram SA, Donaldson PT, Daly AK, Francis RM, Mansfield JC, Thompson NP.

Gut. 2005 Nov;54(11):1579-84. Epub 2005 Jul 11.

20.

Efficacy of oral etidronate for skeletal diseases in Japan.

Iwamoto J, Takeda T, Sato Y.

Yonsei Med J. 2005 Jun 30;46(3):313-20. Review.

Items per page

Supplemental Content

Write to the Help Desk